MedPath

T Cell Validation Study Using Blood Samples From Subjects With Recent Onset Type 1 Diabetes Mellitus

Completed
Conditions
Type 1 Diabetes Mellitus
Registration Number
NCT00212329
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Brief Summary

Type 1 diabetes is a condition that is caused in part by an abnormality of the immune system which occurs when T cells, which are part of the immune system, damage the insulin secreting cells (islet cells) in the pancreas. Although it is known that T cells are important mediators of the disease, progress in the development of reliable T cell assays has been modest. The purpose of this study is to learn which T cell assays are most reliable and reproducible so that the investigators can improve their understanding about how type 1 diabetes occurs.

Detailed Description

The T Cell Validation Study is designed to determine the ability of T cell assays to identify differences in responses from participants with type 1 diabetes compared to normal control subjects, and to compare four different laboratory tests which examine T cells to determine whether the measurements are quantitatively reproducible.

Antibody assays that confirm the presence of type 1 diabetes will be evaluated including: Diabetes Biochemical Autoantibody Assay (anti-GAD65, anti-ICA512, anti-insulin) and Islet Cell Autoantibody testing; genetic testing (deoxyribonucleic acid \[DNA\] and human leukocyte antigen \[HLA\]) will also be done to learn more about the T cell assays.

The following T Cell Assays will be conducted in individuals with type 1 diabetes, as well as those without type 1 diabetes:

* Cellular Immunoblot Testing

* T Cell Proliferation Assay

* Tetramer Assay

* Cytokine ELISpot Assay

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
100
Inclusion Criteria

To be eligible, individuals with type 1 diabetes must be:

  • Diagnosed with type 1 diabetes within one year of first study visit
  • 8-35 years of age at time of first visit
  • Weigh > 40 kg (88 lbs) at time of first visit
  • Individuals who will serve as control subjects who do not have type 1 diabetes cannot have a first degree or second degree relative with type 1 diabetes.
Exclusion Criteria

Individuals must not:

  • Have any major illness
  • Be taking any steroid medications
  • If female, should not be pregnant or breastfeeding.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (14)

Childrens Hospital of Los Angeles

🇺🇸

Los Angeles, California, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

Stanford University Medical Center

🇺🇸

Stanford, California, United States

Barbara Davis Center for Childhood Diabetes

🇺🇸

Denver, Colorado, United States

University of Florida

🇺🇸

Gainesville, Florida, United States

University of Miami School of Medicine

🇺🇸

Miami, Florida, United States

Riley Hospital for Children

🇺🇸

Indianapolis, Indiana, United States

Joslin Diabetes Center

🇺🇸

Boston, Massachusetts, United States

University of Minnesota

🇺🇸

Minneapolis, Minnesota, United States

Naomi Berrie Diabetes Center, Columbia University

🇺🇸

New York, New York, United States

Scroll for more (4 remaining)
Childrens Hospital of Los Angeles
🇺🇸Los Angeles, California, United States
© Copyright 2025. All Rights Reserved by MedPath